The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Open accessAbstract
BACKGROUND: Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors. METHODS: We enrolled participants who were 12 years of age or older. Those who had previously received episodic treatment with bypassing agents were randomly assigned in a 2:1 ratio to emicizumab prophylaxis (group A) or no prophylaxis (group B). The primary end point was the difference in bleeding rates between group A and group B. Participants who had previously received prophylactic treatment with bypassing agents received emicizumab prophylaxis in group C. RESULTS: A total of 109 male participants with hemophilia A with inhibitors were enrolled. The annualized bleeding rate was 2.9 events (95% confidence interval [CI], 1.7 to 5.0) among participants who were randomly assigned to emicizumab prophylaxis (group A, 35 participants) versus 23.3 events (95% CI, 12.3 to 43.9) among those assigned to no prophylaxis (group B, 18 participants), representing a significant difference of 87% in favor of emicizumab prophylaxis (P<0.001). A total of 22 participants in group A (63%) had zero bleeding events, as compared with 1 participant (6%) in group B. Among 24 participants in group C who had participated in a noninterventional study, emicizumab prophylaxis resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing-agent prophylaxis (P<0.001). Overall, 198 adverse events were reported in 103 participants receiving emicizumab prophylaxis; the most frequent events were injection-site reactions (in 15% of participants). Thrombotic microangiopathy and thrombosis were reported in 2 participants each (in the primary analysis) who had received multiple infusions of activated prothrombin complex concentrate for breakthrough bleeding. No antidrug antibodies were detected. CONCLUSIONS: Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no prophylaxis among participants with hemophilia A with inhibitors. (Funded by F. Hoffmann-La Roche and Chugai Pharmaceutical; HAVEN 1 ClinicalTrials.gov number, NCT02622321 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walters, S. J., & Brazier, J. E. (2005) · Quality of Life Research · doi:10.1007/s11136-004-7713-0 · Cited by 1,341
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
Self-citationFactor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478
Self-citationGringeri, A., Mantovani, L. G., Scalone, L., Mannucci, P. M., & the COCIS Study Group (2003) · Blood · doi:10.1182/blood-2003-03-0941 · Cited by 372
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Uchida, N., Sambe, T., Yoneyama, K., Fukazawa, N., Kawanishi, T., Kobayashi, S., & Shima, M. (2016) · Blood · doi:10.1182/blood-2015-06-650226 · Cited by 260
Self-citationFactor VIII inhibitors in hemophilia A: rationale and latest evidence
Witmer, C., & Young, G. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620712464509 · Cited by 231
Self-citationProthrombin complex concentrates: an update.
Franchini, M., & Lippi, G. (2010) · PubMed · doi:10.2450/2010.0149-09 · Cited by 201
Mahlangu, J. N., Kuliczkowski, K., Karim, F. A., Stasyshyn, O., Kosinova, M. V., Lepatan, L. M., Skotnicki, A. B., Boggio, L. N., Klamroth, R., Oldenburg, J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-687434 · Cited by 92
Self-citationInterpreting important health‐related quality of life change using the Haem‐A‐QoL
Wyrwich, K. W., Krishnan, S., Poon, J. L., Auguste, P., von Maltzahn, R., Yu, R., & Mackensen, S. V. (2015) · Haemophilia · doi:10.1111/hae.12642 · Cited by 50
Physical Functioning in Boys with Hemophilia in the U.S.
Monahan, P. E., Baker, J., Riske, B., & Soucie, J. M. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.09.017 · Cited by 45
Coronary artery bypass surgery in a patient with Haemophilia A: a case report
Menard, C. E., Zawadski, D. K., Singal, R. K., Rimmer, E. K., Houston, D. S., Houston, B. L., & Zarychanski, R. (2015) · Haemophilia · doi:10.1111/hae.12864 · Cited by 9
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
WFH Guidelines for the Management of Hemophilia, 3rd edition
Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M. V., Windyga, J., et al. (2020) · Haemophilia · doi:10.1111/hae.14046 · Cited by 2,033
Self-citationBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M. E., Schmitt, C., Jiménez-Yuste, V., Kempton, C., Dhalluin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803550 · Cited by 763
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., Valente, N., Asikanius, E., Levy, G. G., Windyga, J., & Shima, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2734287351
- Cited by
- 1,121
- References
- 16
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.